MJN110

Endocannabinoids such as 2-arachidonoyl glycerol (2-AG; Item No. 62160) and arachidonoyl ethanolamide (AEA; Item No. 90050) are biologically active lipids that are involved in a number of synaptic processes including activation of cannabinoid receptors. Monoacylglycerol lipase (MAGL) is a serine hydrolase responsible for the hydrolysis of 2-AG to arachidonic acid (Item No. 90010) and glycerol, thus terminating its biological function. MJN110 is an N-hydroxysuccinimidyl carbamate that inhibits MAGL (IC₅₀ = 9.1 nM) and to a lesser extent ABHD6 with potent selectivity over FAAH (IC₅₀ > 10 µM) and other brain serine hydrolases.¹ It can inhibit 2-AG hydrolysis (IC₅₀ = 2.1 nM) with no effect on AEA hydrolysis up to 50 µM.¹ At 5 mg/kg, MJN110 has been shown to alleviate mechanical allodynia in a rat model of diabetic neuropathy.¹

WARNING This product is not for human or veterinary use.

1. Niphakis, M.J., Cognetta, A.B., III, Chang, J.W., et al. Evalulation of NHS carbamates as a potent and selective class of endocannabinoid hydrolase inhibitors. ACS Chem. Neurosci. 4(9), 1322-1332 (2013).